Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
330 hedge funds and large institutions have $9.13B invested in Acceleron Pharma in 2021 Q3 according to their latest regulatory filings, with 96 funds opening new positions, 86 increasing their positions, 105 reducing their positions, and 35 closing their positions.
197% more call options, than puts
Call options by funds: $578M | Put options by funds: $195M
174% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 35
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
36% more capital invested
Capital invested by funds: $6.72B → $9.13B (+$2.41B)
22% more funds holding
Funds holding: 271 → 330 (+59)
18% less repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 105
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$137M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$131M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$109M |
| 4 |
VI
Versor Investments
New York
|
+$52.5M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$132M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$95.6M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$70.2M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$68.8M |
| 5 |
BlackRock
New York
|
-$56.3M |
XLRN Hedge Fund Activity: Q3 2021 in Review
330 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2021, worth a combined $9.13B — up 36% from $6.72B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new XLRN positions and 35 closed out — a net gain of 61 holders — while 86 added to existing stakes and 105 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $137M. The largest seller was Wellington Management Group, cutting an estimated $132M.
- 330 institutional investors held Acceleron Pharma (XLRN) as of Q3 2021, up from 271 in Q2 2021.
- Funds reported $9.13B of Acceleron Pharma stock for Q3 2021, up 36% quarter-over-quarter.
- 96 funds opened new Acceleron Pharma positions in Q3 2021 and 35 closed out, a net change of +61 holders.
- The largest Acceleron Pharma buyer in Q3 2021 was Pentwater Capital Management, an estimated $137M added.
- The largest Acceleron Pharma seller in Q3 2021 was Wellington Management Group, an estimated $132M sold.
Based on aggregated 13F filings for Q3 2021.